CSIMarket
 
Harrow Inc   (NASDAQ: HROW)
 
Price: $34.3500 $0.51 1.507%
Day's High: $34.38999938964844 Week Perf: -6.1 %
Day's Low: $ 33.84 30 Day Perf: -12.99 %
Volume (M): 99,303 52 Wk High: $ 54.85
Volume (M$): $ 0 52 Wk Avg: $41.05
Open: $33.85 52 Wk Low: $28.54



 Market Capitalization (Millions $) 1,283
 Shares Outstanding (Millions) 37
 Employees 382
 Revenues (TTM) (Millions $) 275
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 42
 Capital Exp. (TTM) (Millions $) 1

Business Description


Harrow Health Inc is a publicly-traded, US-based company that specializes in designing, developing and marketing branded prescription and over-the-counter (OTC) pharmaceutical products. The company was founded in 2017 and is headquartered in Nashville, Tennessee. Harrow Health is led by its CEO, Mark L. Baum, who has over 30 years of experience in the pharmaceutical industry.

The company's business model is centered around the development and commercialization of high-quality, affordable and innovative drug products. Harrow Health focuses primarily on niche markets, targeting pharmaceuticals that are used to treat underserved diseases and conditions. The company has an experienced team of medical professionals, researchers and executives who are committed to driving growth through a blend of branded and generic drug products.

Harrow Health's portfolio includes FDA-approved branded drugs and OTC products for the treatment of hypothyroidism, glaucoma, insomnia, and diminished sex drive among others. The company also has a strong pipeline of products under development, including products targeting dry eye disease, neuropathic pain, and acute migraines.

One of Harrow Health's key strengths is its proprietary technologies - the company has developed unique systems for manufacturing and delivering medications that improve efficiency, reduce waste and reduce overall production costs. This allows Harrow Health to offer its products at competitive prices while maintaining high margins and profitability.

Harrow Health operates through its subsidiaries, ImprimisRx and Park Compounding. ImprimisRx is a compounding pharmacy that specializes in preparing customized medications for patients with specific medical needs. Park Compounding, on the other hand, is focused on developing and testing new formulations, with the goal of improving the effectiveness and tolerability of existing drugs.

Harrow Health's growth strategy includes both organic growth and acquisitions. The company is actively pursuing acquisitions of other pharmaceutical companies and assets that align with its business model and strategic objectives. In addition, Harrow Health is focused on expanding its product offerings and leveraging its existing technologies to launch new products for underserved markets.

Overall, Harrow Health is a dynamic and rapidly-growing pharmaceutical company that is committed to bringing innovative and affordable products to market. With a strong leadership team, proprietary technologies and a robust product pipeline, the company is poised for continued success in the years ahead.


   Company Address: 1A Burton Hills Blvd Nashville 37215 TN
   Company Phone Number: 733-4730   Stock Exchange / Ticker: NASDAQ HROW


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        4.62% 
ALDX   -7.33%    
EOLS   -6.42%    
KALA   -7.32%    
OCUL   -11.2%    
REGN   -4.21%    
• View Complete Report
   



Product Service News

Revolutionizing Ophthalmic Access Harrow Launches HAFA Initiative for Broader Market Reach

Published Fri, Sep 26 2025 4:21 AM UTC

In a move that could significantly impact the accessibility of ophthalmic treatments, Harrow (NASDAQ: HRRO) has recently introduced their Harrow Access for All (HAFA) initiative. This groundbreaking program is designed to enhance market access for their innovative portfolio of ophthalmic products, making essential treatments more readily available to patients who need them t...

Business Update

Harrow Healths Q1 2025 Financial Results Reveal Growth Potential as Investor Engagement Strengthens,

Published Sun, May 11 2025 6:13 PM UTC

Harrow Reports Q1 2025 Financial Results Amid Ongoing Investor Engagement NASHVILLE, Tenn. Harrow Health, Inc. (NASDAQ: HROW), a prominent player in the North American eyecare pharmaceutical space, has announced its financial results for the first quarter ended March 31, 2025. This update continues to underscore the company s commitment to maintaining transparency with it...

Business Update

Harrow Subsidiary Wins $34.9 Million Jury Verdict in Trademark Infringement Case Against OSRX

Published Thu, Nov 21 2024 1:34 PM UTC

In a landmark legal victory, Harrow Health, Inc. (Nasdaq: HROW) proudly announced that its wholly owned subsidiary, ImprimisRx, LLC, has been awarded $34.9 million in a unanimous jury verdict against OSRX, Inc. The case, which was brought before the United States District Court in San Diego, California, centered on allegations of willful trademark infringement, a serious iss...

Business Update

Harrow Inc. to Engage Investors Amid Ongoing Financial Challenges

Published Fri, Nov 15 2024 12:56 PM UTC

Harrow Inc. (Nasdaq: HROW) Announces Participation in Upcoming Conferences NASHVILLE, Tenn. October 2023 Harrow Inc. a prominent eyecare pharmaceutical company based in North America, has announced its participation in three key investor conferences in the coming months. The management team will engage with investors at the Craig-Hallum 15th Annual Alpha Select Conference,...

Business Update

Vision for All Harrow Pioneers Affordable Eyecare Solutions in Collaboration with GoodRx,

Published Wed, Nov 13 2024 1:36 PM UTC

Expanding Access and Affordability: Harrow s Innovative Initiative in Eyecare Pharmaceuticals In recent years, the rising cost of prescription medications has been a major concern among patients, healthcare providers, and policymakers alike. Addressing these concerns requires innovative solutions from pharmaceutical companies willing to rethink traditional pricing strategies...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.67
Price to Sales (Expected) -
Price to Book 84.41
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.82
Working Capital Ratio 2.28
Leverage Ratio (MRQ) 26.44
Total Debt to Equity 19.74
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.99 $
Revenues (TTM) 7.36 $
Cash Flow (TTM) 1.12 $
Cash 2.25 $
Book Value 0.41 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 719,173
Net Income per Employee (TTM) -97,450
Receivable Turnover Ratio (TTM) 2.69
Inventory Turnover Ratio (TTM) 4.93
Asset Turnover Ratio (TTM) 0.69

Profitability Ratios Current
Gross Margin (MRQ) 71.27 %
Operating Margin (MRQ) -15.58 %
Net Margin (MRQ) -24.44 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Harrow Inc's Segments
Product Sales Net    162.33 % of total Revenue
Branded    122.85 % of total Revenue
Compounding    39.7 % of total Revenue
IHEEZO    24.82 % of total Revenue
VEVYE    71.23 % of total Revenue
Other Products    26.57 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.